Encouraging Results for Bexobrutideg in Difficult-to-Treat Blood Cancer

Nurix Therapeutics presented positive Phase 1 data for its BTK degrader, bexobrutideg (NX-5948), showing high response rates and favorable safety in heavily pre-treated Waldenström Macroglobulinemia patients.